Lerociclib (G1T38) is an oral CDK4/6 inhibitor used mainly for treating Hormone Receptor-positive, HER2-negative (HR+/HER2-) advanced or metastatic breast cancer, especially after progression on prior endocrine therapy, often combined with fulvestrant to arrest the cell cycle and slow tumor growth. It works by blocking CDK4/6 proteins, preventing cancer cell proliferation with a generally good safety profile, showing significant progression-free survival benefits in clinical trials like LEONARDA-1, and offering a new option for endocrine-resistant cases. It is grouped under the following drug class(es): CDK4/6 Inhibitors. The directory classifies it as a discontinued API with a synthetic source/manufacturing origin. Other names for this substance include Lerociclibum and G1T-38. Its PubChem CID is 86269224.
Lerociclib
| CAS No | 1628256-23-4 |
|---|---|
| Molecular Formula | C26H34N8O |
| Molecular Weight | 474.60 g/mol |
| Synonyms | 4-[[5-(4-propan-2-ylpiperazin-1-yl)pyridin-2-yl]amino]spiro[1,3,5,11-tetrazatricyclo[7.4.0.02,7]trideca-2,4,6,8-tetraene-13,1'-cyclohexane]-10-one |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Lerociclib (G1T38) is an oral CDK4/6 inhibitor used mainly for treating Hormone Receptor-positive, HER2-negative (HR+/HER2-) advanced or metastatic breast cancer, especially after progression on prior endocrine therapy, often combined with fulvestrant to arrest the cell cycle and slow tumor growth.
The listed CAS number is 1628256-23-4.
The listed molecular formula is C26H34N8O.
The listed molecular weight is 474.60 g/mol.
4-[[5-(4-propan-2-ylpiperazin-1-yl)pyridin-2-yl]amino]spiro[1,3,5,11-tetrazatricyclo[7.4.0.02,7]trideca-2,4,6,8-tetraene-13,1'-cyclohexane]-10-one.
The source lists Lerociclibum and G1T-38.